Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Robert W. Baird upgraded shares of Diplomat Pharmacy to a “positive” rating and raised their price target for the stock from $20.00 to $24.00 in a report on Monday, September 18th. Needham & Company LLC began coverage on shares of Diplomat Pharmacy in a research note on Friday, July 21st. They issued a “buy” rating and a $19.75 price objective on the stock. Finally, TheStreet raised shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $19.16.

Shares of Diplomat Pharmacy (NYSE DPLO) opened at 21.57 on Thursday. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $29.36. The company has a 50-day moving average of $18.89 and a 200 day moving average of $16.86. The company has a market capitalization of $1.47 billion, a PE ratio of 117.87 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the company posted $0.23 earnings per share. Analysts predict that Diplomat Pharmacy will post $0.75 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/diplomat-pharmacy-inc-dplo-rating-increased-to-strong-buy-at-bidaskclub/1614182.html.

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in shares of Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Diplomat Pharmacy by 13.8% during the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after purchasing an additional 1,073 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC bought a new position in shares of Diplomat Pharmacy during the first quarter valued at about $160,000. 69.89% of the stock is currently owned by hedge funds and other institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.